Skip to main content
    L

    LeMaitre Vascular Inc (LMAT)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $77.01
    -1.28 (-1.63%)

    Market Cap: $1.79B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    LeMaitre Vascular Inc (LMAT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    LeMaitre Vascular (LMAT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, LeMaitre Vascular reported EPS of $0.65, below the $0.69 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    54%(21/39)
    Avg Surprise
    +5.46%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.74
    Range$0.71 - $0.78
    10 analysts
    Revenue Consensus
    $72.48M
    Range$69.46M - $74.91M
    10 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.76
    Range$0.74 - $0.77
    5 analysts
    EPS Revisions
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.76-0.9%
    60d ago$0.76-0.9%
    30d ago$0.76-0.9%
    7d ago$0.76-0.9%
    Current$0.76
    Revenue Consensus
    $73.20M
    Range$73.00M - $73.41M
    4 analysts

    Next Report

    LMAT has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.8% above the $0.68 reported for the quarter ended Dec 31, 2025.

    LMAT Earnings Call

    The latest LMAT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, LMAT beat 21, missed 13 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $67.97M, up 11.3% from $61.05M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.65$0.69$0.68 - $0.69-5.80%Miss-13.3%80 up, 8 downNov 4, 2026$67.97M
    Jun 30, 2026$0.74$0.81$0.79 - $0.82-8.64%Miss+23.3%97 up, 0 downAug 4, 2026$70.38M
    Mar 31, 2026$0.68$0.66$0.64 - $0.68+3.03%Beat+41.7%96 up, 0 downMay 5, 2026$66.55M
    Dec 31, 2025$0.68$0.66$0.63 - $0.68+3.03%Beat+38.8%101 up, 0 downFeb 25, 2026$64.45M
    Sep 30, 2025$0.75$0.56$0.54 - $0.58+33.93%Beat+53.1%80 up, 0 downNov 6, 2025$61.05M
    Jun 30, 2025$0.60$0.57$0.55 - $0.58+5.26%Beat+15.4%91 up, 4 downAug 5, 2025$64.23M
    Mar 31, 2025$0.48$0.50$0.48 - $0.52-4.00%Miss+9.1%91 up, 1 downMay 1, 2025$59.87M
    Dec 31, 2024$0.49$0.49$0.47 - $0.520.00%In line+28.9%95 up, 0 downFeb 27, 2025$55.72M
    Sep 30, 2024$0.49$0.43$0.42 - $0.45+13.95%Beat+48.5%100 up, 0 downOct 31, 2024$54.82M
    Jun 30, 2024$0.52$0.47$0.45 - $0.49+10.64%Beat+40.5%90 up, 0 downAug 1, 2024$55.85M
    Mar 31, 2024$0.44$0.39$0.37 - $0.40+12.82%Beat+63.0%80 up, 0 downMay 2, 2024$53.48M
    Dec 31, 2023$0.38$0.36$0.34 - $0.37+5.56%Beat+52.0%91 up, 0 downFeb 27, 2024$48.88M
    Sep 30, 2023$0.33$0.30$0.28 - $0.32+10.00%Beat+32.0%60 up, 0 downNov 1, 2023$47.41M
    Jun 30, 2023$0.37$0.32$0.30 - $0.34+15.63%Beat+27.6%70 up, 0 downAug 1, 2023$50.12M
    Mar 31, 2023$0.27$0.25$0.24 - $0.26+8.00%Beat0.0%70 up, 0 downMay 2, 2023$47.08M
    Dec 31, 2022$0.25$0.26$0.24 - $0.29-3.85%Miss-10.7%70 up, 0 downFeb 23, 2023$40.95M
    Sep 30, 2022$0.25$0.28$0.27 - $0.31-10.71%Miss-16.7%80 up, 0 downOct 27, 2022$39.03M
    Jun 30, 2022$0.29$0.30$0.22 - $0.36-3.33%Miss-27.5%81 up, 0 downJul 28, 2022$42.11M
    Mar 31, 2022$0.27$0.28$0.26 - $0.28-3.57%Miss-3.6%70 up, 0 downApr 28, 2022$39.56M
    Dec 31, 2021$0.28$0.31$0.29 - $0.32-9.68%Miss-17.6%80 up, 1 downFeb 24, 2022$39.50M
    Sep 30, 2021$0.30$0.33$0.31 - $0.35-9.09%Miss-14.3%8N/AOct 28, 2021$38.37M
    Jun 30, 2021$0.40$0.36$0.29 - $0.40+11.11%Beat+90.5%6N/AJul 29, 2021$40.67M
    Mar 31, 2021$0.28$0.27$0.24 - $0.29+3.70%Beat+75.0%6N/AApr 29, 2021$35.88M
    Dec 31, 2020$0.34$0.29$0.25 - $0.32+17.24%Beat+47.8%6N/AFeb 25, 2021$37.55M
    Sep 30, 2020$0.35$0.19$0.17 - $0.22+84.21%Beat+40.0%5N/AOct 29, 2020$36.42M
    Jun 30, 2020$0.21$0.01-$0.09 - $0.13N/AN/A-8.7%6N/AJul 23, 2020$24.85M
    Mar 31, 2020$0.16$0.16$0.12 - $0.170.00%In line-5.9%6N/AApr 30, 2020$30.55M
    Dec 31, 2019$0.23$0.23$0.22 - $0.230.00%In line+21.1%7N/AFeb 6, 2020$30.17M
    Sep 30, 2019$0.25$0.21$0.20 - $0.22+19.05%Beat+19.0%7N/AOct 23, 2019$29.10M
    Jun 30, 2019$0.23$0.21$0.20 - $0.22+9.52%Beat+9.5%7N/AJul 24, 2019$29.48M
    Mar 31, 2019$0.17$0.19$0.19 - $0.20-10.53%Miss-10.5%7N/AMay 1, 2019$28.48M
    Dec 31, 2018$0.19$0.19$0.18 - $0.240.00%In line-9.5%6N/AFeb 19, 2019$28.39M
    Sep 30, 2018$0.21$0.21$0.20 - $0.220.00%In line-16.0%7N/AOct 4, 2018$24.16M
    Jun 30, 2018$0.21$0.42$0.41 - $0.43-50.00%Miss-8.7%8N/AJul 26, 2018$27.02M
    Mar 31, 2018$0.19$0.21$0.20 - $0.23-9.52%Miss+18.8%6N/AApr 25, 2018$25.99M
    Dec 31, 2017$0.21$0.20$0.19 - $0.21+5.00%Beat+61.5%6N/AFeb 21, 2018$26.15M
    Sep 30, 2017$0.25$0.20$0.20 - $0.21+25.00%Beat+47.1%8N/AOct 26, 2017$24.82M
    Jun 30, 2017$0.23$0.17$0.17 - $0.17+35.29%Beat+64.3%8N/AJul 27, 2017$25.75M
    Mar 31, 2017$0.16$0.13N/A+23.08%Beat+45.5%N/AN/AApr 26, 2017$24.14M
    Dec 31, 2016$0.13$0.15N/A-13.33%Miss0.0%N/AN/AFeb 21, 2017$23.29M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.51, up 29.4% from the year before. It was $0.55 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.51+29.4%
    Dec 31, 2024$1.94+43.7%
    Dec 31, 2023$1.35+27.4%
    Dec 31, 2022$1.06-15.9%
    Dec 31, 2021$1.26+18.9%
    Dec 31, 2020$1.06+20.5%
    Dec 31, 2019$0.88+10.0%
    Dec 31, 2018$0.80-5.9%
    Dec 31, 2017$0.85+54.5%
    Dec 31, 2016$0.55N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,41910
    2026Q2Jun 30, 20263,94110
    2026Q1Mar 31, 20264,23113
    2025Q4Dec 31, 20255,89412
    2025Q3Sep 30, 20256,78013
    2025Q2Jun 30, 20255,05114
    2025Q1Mar 31, 20256,80010
    2024Q4Dec 31, 20244,13213

    2026Q3 Earnings Call

    Opening remarks

    Dorian LeBlanc CFO Good afternoon, and thank you for joining us on our Q3 2026 conference call. With me on today's call is our CEO, George LeMaitre. Before we begin, I will read our safe harbor statement. Today, we will be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast, might, and similar expressions. Our forward-looking statements are based on our estimates and assumptions as of today, November 4, 2026, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the cautionary statement regarding forward-looking information and the risk factors in our most recent 10-K and subsequent SEC filings, including disclosure of the factors that could cause results to differ materially from those expressed or implied. During this call, we will discuss non-GAAP financial measures such as organic sales growth. A reconciliation of GAAP to non-GAAP measures discussed in this call is contained in the associated press release and in the investor relations section of our website, www.lemaitre.com. I will now turn the call over to George LeMaitre.

    George LeMaitre CEO Thanks, Dorian. Sales grew 12% organically in Q3, 7% from price and 5% from units. Grafts grew 20% and shunts 14%. Biologics continued to outpace the rest of our portfolio, as Artegraft was up 18% and RestoreFlow allografts were up 34%. Geographically, EMEA sales increased 18%, the Americas 9%, and APAC 5%. On October 14, we acquired several devices from B. Braun: polyester and silver-coated vascular grafts, valve cutters, and vein strippers. This is our third polyester graft acquisition since 2007, and we look set to become number three in worldwide share, excluding Japan. We have always wanted to offer silver-coated vascular grafts, as they are designed to resist infection. The acquired portfolio posted 2025 sales of $9.4 million, all outside North America. Sixty-five percent of sales were in Europe, including 21% in Germany, our second-largest market. While the sales transition will take about two years, this acquisition is right out of our playbook. We acquire niche vascular and cardiac products and grow them through our global sales channel. As for Artegraft, we are investing in the product in several ways. Number one, more international approvals. Number two, increased lengths for leg bypasses. Number three, building out our commercial infrastructure and sales force. Q3 international Artegraft sales were $3 million, and we continue to expect full-year sales of more than $11 million. In Q3, we received approvals in Brazil and Saudi Arabia, bringing us to 60 countries.

    Frequently Asked Questions About LMAT

    When is LeMaitre Vascular's next earnings date?

    LeMaitre Vascular's next earnings report is expected for Feb 23, 2027.

    Did LMAT beat earnings estimates last quarter?

    No. LeMaitre Vascular reported EPS of $0.65 for the quarter ended Sep 30, 2026, below the $0.69 estimate by 5.80%.

    What EPS do analysts expect from LMAT next quarter?

    The consensus EPS estimate for LeMaitre Vascular for the quarter ending Dec 31, 2026 is $0.74 from 10 analysts, with estimates from $0.71 to $0.78.

    How often does LMAT beat earnings estimates?

    LeMaitre Vascular beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.35%.